- Home
- KROS vs PLRX Comparison
KROS vs PLRX Comparison
Compare KROS & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KROS
- PLRX
- Stock Information
- Founded
- KROS 2015
- PLRX 2015
- Country
- KROS United States
- PLRX United States
- Employees
- KROS N/A
- PLRX N/A
- Industry
- KROS Biotechnology: Pharmaceutical Preparations
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- KROS Health Care
- PLRX Health Care
- Exchange
- KROS Nasdaq
- PLRX Nasdaq
- Market Cap
- KROS 460.6M
- PLRX 680.3M
- IPO Year
- KROS 2020
- PLRX 2020
- Fundamental
- Price
- KROS $11.00
- PLRX $11.37
- Analyst Decision
- KROS Buy
- PLRX Strong Buy
- Analyst Count
- KROS 11
- PLRX 7
- Target Price
- KROS $45.33
- PLRX $40.50
- AVG Volume (30 Days)
- KROS 2.1M
- PLRX 485.5K
- Earning Date
- KROS 02-26-2025
- PLRX 02-26-2025
- Dividend Yield
- KROS N/A
- PLRX N/A
- EPS Growth
- KROS N/A
- PLRX N/A
- EPS
- KROS N/A
- PLRX N/A
- Revenue
- KROS $651,000.00
- PLRX N/A
- Revenue This Year
- KROS $303.27
- PLRX N/A
- Revenue Next Year
- KROS N/A
- PLRX N/A
- P/E Ratio
- KROS N/A
- PLRX N/A
- Revenue Growth
- KROS 8037.50
- PLRX N/A
- 52 Week Low
- KROS $9.78
- PLRX $10.22
- 52 Week High
- KROS $73.00
- PLRX $18.00
- Technical
- Relative Strength Index (RSI)
- KROS 24.79
- PLRX 44.60
- Support Level
- KROS $11.04
- PLRX $10.35
- Resistance Level
- KROS $11.99
- PLRX $11.07
- Average True Range (ATR)
- KROS 0.60
- PLRX 0.61
- MACD
- KROS 1.20
- PLRX 0.06
- Stochastic Oscillator
- KROS 43.99
- PLRX 43.50
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.